Dr. Reddy's is recalling Olanzapine tablets, for the treatment of schizophrenia and bipolar disorder, and Aurobindo Pharma is withdrawing injectable Pantoprazole sodium, used to treat gastroesophageal reflux, after receiving FDA warning letters. Both are voluntary Class III recalls, indicating negative health consequences are unlikely.
The Scottish Medicines Consortium has recommended six drugs for National Health Service use in Scotland to treat cancer, chronic migraine, high cholesterol and iron deficiency. The drugs include: AstraZeneca's Tagrisso, Novartis' Afinitor, Servier Laboratories' Lonsurf, Allergan's Botox, Amgen's Repatha and Pharmacosmos' Diafer.
The European Commission has approved the use of Incyte and Eli Lilly and Co.'s Olumiant, or baricitinib, as a treatment for moderate to severe rheumatoid arthritis in adults who are intolerant to or have an inadequate response to disease-modifying anti-rheumatic drugs. The drug is expected to be launched this year.
Researchers from the Gustave Roussy Cancer Institute in France found that disease progression was more rapid among the 80 study patients with metastatic renal cell carcinoma who took antibiotics within a month before their scheduled cancer immunotherapy session compared with those who didn't. The findings were presented at a presscast prior to the Genitourinary Cancers Symposium being held in Florida.
China-based ApolloBio has gained exclusive rights to develop Inovio Pharmaceuticals' VGX-3100, a late-stage vaccine candidate designed to prevent and treat precancerous infections and dysplasias related to human papillomavirus, in China, Taiwan, Hong Kong and Macao. Under the collaboration and licensing deal, Inovio will receive a $3 million upfront payment and is eligible for a $12 million near-tern payment and $20 million in regulatory milestones, along with sales royalties.
An order has been issued by India's National Pharmaceutical Pricing Authority capping prices of bare-metal coronary stents at approximately $109 per unit and of metallic drug-eluting stents and bioresorbable vascular scaffold or biodegradable stents at approximately $442 per unit effective immediately.
A letter was sent to HHS Secretary Tom Price by Sens. Chuck Grassley, R-Iowa, John McCain, R-Ariz., and Amy Klobuchar, D-Minn., requesting immediate approval for Canadian import of prescription drugs in response to price hikes. The senators noted that Price has the authority to allow imports under four circumstances, including a "significant and unexplained increase in price," such as the recently approved Duchenne muscular dystrophy treatment that was set to be priced over 50 times its cost in Canada.
A Persistence Market Research report predicts the worldwide market for cervical total disc replacement devices will reach $1.75 billion by 2021 with a 23.1% compound annual growth rate due to the expanding aging population and the increasing incidence of chronic diseases. Among the key market players are Medtronic, DePuy Synthes, NuVasive and Globus Medical.
DIA's Advertising and Promotion Regulatory Affairs Conference dives deep into the latest best practices, how to avoid potential legal implications, mobile app considerations, ad promo submissions and how to handle FDA inspections. Whether you are new to the field or have years of experience, you can't afford to miss this opportunity to prepare yourself for what's coming! Learn the five keys to building the bridge with FDA on advertising and promotion challenges. View the infographic.